Table 2

Description of periprocedural anticoagulation

Bassiouny et al15Bernard et al23Haines et al16Ichiki et al24Kaseno et al17Kim et al18Lakkireddy et al9Maddox et al19Mendoza et al25Nin et al20Pavaci et al26Rowley et al27Snipelisky et al.21Yamaji et al22
Patients treated with dabigatran3761552223011019114521260452711331106
Dabigatran dosage150 mg twice dailyNA150 mg twice daily*NA110 mg twice daily150 mg twice daily150 mg twice daily150 mg twice daily150 mg twice daily110 mg twice dailyNANA150 mg twice daily110 mg twice daily in 36
150 mg twice daily in 70
Timing of first held dose of dabigatrainMorning of the day of the procedure or the night before24 h≤12 h in 35
12–24 h in 29
24–48 h in 102
>48 h in 18
Unknown in 18		Morning of procedureMorning of procedureNight before procedureMorning of procedureUninterruptedMorning of procedureMorning of the day before procedureNADay before procedureMorning of procedureMorning of the day of the procedure
Time interval for restarting after procedureAfter arousal from anesthesia/sedationWithin 24 h≤6 h in 116
6–24 h in 83
>24 h in 1
Unknown in 2		NAMorning after procedure4 h3 hUninterruptedImmediately after sheath removal (144.3 min)4 h after haemostasis at the puncture siteNA> 24 h (day following)Evening of procedureSingle dose, 3 h after the completion of the procedure
Patients treated with warfarin62344222180101572145251584527169125397
Timing of first held dose of warfarinUninterruptedUninterrupted≤12 h in 74
12–24 h in 88
24–48 h in 15
>48 h in 25		UninterruptedUninterruptedUninterruptedUninterruptedUninterruptedUninterruptedMorning of the day before procedureUninterruptedDay before procedureEvening prior to the procedureUninterrupted in 203 patients.
Interrupted 48 h before in 194
Timing for restarting warfarinUninterruptedUninterruptedDay of the procedureUninterruptedUninterruptedUninterruptedUninterruptedUninterruptedUninterrupted4 h after haemostasis at the puncture siteUninterruptedDay after procedureEvening of procedureDay after procedure in patients who stopped warfarin
Target ACT (seconds) during procedure350–450NA300–350 at leastNA300–350300–350300–400>350–400300–350300–400250–300NA>350300–350
Follow-up duration1 month1 monthPeriprocedural/ hospital dischargeNAAt least 2 months3 months30 daysPeriprocedural/ hospital discharge1 month2 weeksNA30 days1 week3 months

  • *Except for one elderly patient who took the 110 mg twice daily dose.

  • ACT, activated clotting time; NA, not available.